Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis
- Written by PR Newswire
![]() |
LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC). This license agreement marks a pivotal step with PharusDx to...















